RecruitingNCT06860958
Roflumilast added to antidepressants for major depression
About this title
Read the official source — NCT06860958Medication studyAges 18–65Egypt
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- TantaSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 1, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 60
- Sponsor
- Tanta University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Egypt
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06860958
- Official title
Show the full official title
Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Tanta
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Tanta University, a university.
Does this study involve medication?
Yes. The study involves medication, including Fluoxetine, Roflumilast and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
